A detailed history of Gsa Capital Partners LLP transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 1,775,700 shares of KPTI stock, worth $1.28 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
1,775,700
Previous 983,417 80.56%
Holding current value
$1.28 Million
Previous $853,000 72.8%
% of portfolio
0.11%
Previous 0.06%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$0.7 - $1.06 $554,598 - $839,819
792,283 Added 80.56%
1,775,700 $1.47 Million
Q2 2024

Aug 15, 2024

SELL
$0.87 - $1.58 $274,688 - $498,859
-315,734 Reduced 24.3%
983,417 $853,000
Q1 2024

May 03, 2024

SELL
$0.72 - $1.66 $747,960 - $1.72 Million
-1,038,834 Reduced 44.43%
1,299,151 $1.96 Million
Q4 2023

Feb 16, 2024

BUY
$0.68 - $1.31 $1.2 Million - $2.32 Million
1,769,687 Added 311.4%
2,337,985 $2.01 Million
Q3 2023

Nov 15, 2023

BUY
$1.14 - $1.81 $647,859 - $1.03 Million
568,298 New
568,298 $761,000
Q4 2022

Feb 13, 2023

BUY
$2.48 - $5.93 $203,761 - $487,220
82,162 New
82,162 $279,000
Q1 2022

May 11, 2022

SELL
$5.91 - $14.38 $1.13 Million - $2.76 Million
-191,976 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$5.21 - $8.61 $78,045 - $128,977
14,980 Added 8.46%
191,976 $1.23 Million
Q3 2021

Nov 12, 2021

BUY
$4.45 - $10.63 $657,968 - $1.57 Million
147,858 Added 507.44%
176,996 $1.03 Million
Q2 2021

Aug 05, 2021

SELL
$8.11 - $11.11 $11,791 - $16,153
-1,454 Reduced 4.75%
29,138 $301,000
Q1 2021

May 10, 2021

BUY
$9.85 - $17.69 $85,586 - $153,708
8,689 Added 39.67%
30,592 $322,000
Q4 2020

Feb 03, 2021

BUY
$14.15 - $17.19 $309,927 - $376,512
21,903 New
21,903 $339,000

Others Institutions Holding KPTI

About Karyopharm Therapeutics Inc.


  • Ticker KPTI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 79,806,600
  • Market Cap $57.5M
  • Description
  • Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...
More about KPTI
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.